We’ll use private healthcare to cut NHS waiting lists, Labour says June 4, 2024 Labour will use “spare capacity in the private sector” to reduce NHS waiting lists, Wes Streeting has said.
Record-breaking private health admissions, amid NHS crisis June 4, 2024 Admissions funded by private medical insurance were at record levels, going above pre-pandemic figures for the first time.
Can this device help back pain caused by sitting at your desk? June 1, 2024 Sitting for eight or more hours a day at a desk isn't natural for our bodies, which is why prolonged sitting can cause back pain.
Labour warned promise to clear NHS backlog ‘highly stretching’ May 29, 2024 Labour have been warned their pledge to clear the NHS backlog within five years will prove “highly stretching” and “no easy feat” by economists and policy experts.
Wellness Wonders: Meet the founders of probiotic supplements brand Heights May 26, 2024 Mental health advocate Dan Murray-Serter and serial entrepreneur Joel Freeman, are the co-founders of the science-backed supplement brand Heights.
Protein Works: Sales and profit spike at challenger brand May 24, 2024 The company behind challenger brand Protein Works saw its sales and profits jump during its latest financial year.
Non-invasive filler alternatives for healthier-looking skin May 23, 2024 When wrinkles appear and gravity takes its toll on your face, you might consider invasive treatments like botox and fillers. But with skincare tech improving, it's worth holding off.
Infected blood scandal: Compensation payments to start this year, minister says May 21, 2024 Compensation payments to the victims and families of the infected blood scandal will begin before the end of the year, the government has confirmed.
Based in an old Bermondsey biscuit factory, this London cancer drug firm just raised millions May 21, 2024 Founded in 2012 by a PhD student, Labgenius uses technology to create more effective and safer antibodies for cancer treatment.
‘New era of growth’: FTSE 100 giant Astrazeneca aims to double revenue May 21, 2024 London-listed Astrazeneca reported revenue of $45.8bn in 2023 and growth of 19 per cent to $12.7bn in the first quarter of 2024.